Aduhelm struggles barely affected CEO Michel Vounatsos' $17.7M pay
Last year was a difficult one for Biogen, as it got off to a rough start with its controversial Alzheimer’s drug Aduhelm — but that barely crimped CEO Michel Vounatsos’ pay.
Vounatsos saw a $1 million pay cut last year, raking in nearly $17.7 million. That’s not so bad, considering he took home just over $18.6 million the year before. And Moderna’s Stéphane Bancel came away from the company’s mRNA success last year with $18.2 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.